Candriam SCA’s BridgeBio Pharma BBIO Stock Holding History

Candriam SCA’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$20.7M	Hold	278,888	–	–	0.11%	190
2025 Q4	$21.3M	Buy	278,888 +129,902	+87%	+$8.53M	0.11%	182
2025 Q3	$7.74M	Buy	+148,986	New	+$7.27M	0.04%	304
2024 Q2	–	Sell	-380,000	Closed	-$11.7M	–	693
2024 Q1	$11.7M	Buy	380,000 +81,000	+27%	+$2.75M	0.08%	240
2023 Q4	$12.1M	Buy	299,000 +54,000	+22%	+$1.62M	0.08%	231
2023 Q3	$6.46M	Sell	245,000 -40,000	-14%	-$1.14M	0.05%	284
2023 Q2	$4.9M	Hold	285,000	–	–	0.04%	335
2023 Q1	$4.35M	Buy	285,000 +188,756	+196%	+$2.2M	0.03%	396
2022 Q4	$733K	Buy	96,244 +469	+0.5%	+$4.49K	﹤0.01%	758
2022 Q3	$952K	Sell	95,775 -306,137	-76%	-$3.18M	0.01%	717
2022 Q2	$3.65M	Hold	401,912	–	–	0.03%	376
2022 Q1	$4.08M	Hold	401,912	–	–	0.03%	392
2021 Q4	$6.7M	Sell	401,912 -53,373	-12%	-$2.26M	0.04%	306
2021 Q3	$21.3M	Hold	455,285	–	–	0.15%	166
2021 Q2	$27.8M	Buy	+455,285	New	+$26M	0.19%	124

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Candriam SCA's BBIO Position: Q1 2026 in Review

Candriam SCA held its BridgeBio Pharma (BBIO) position steady in Q1 2026 at 278,888 shares worth $20.7M. The position accounts for 0.11% of the portfolio, ranked #190.

Candriam SCA first reported a position in BBIO in Q2 2021 and has held it in 15 quarters since. The position peaked at $27.8M in Q2 2021. 457 funds tracked by Wall St. Rank hold BBIO as of Q1 2026.

Candriam SCA held 278,888 shares of BridgeBio Pharma worth $20.7M as of Q1 2026.
Candriam SCA left its BridgeBio Pharma share count unchanged in Q1 2026.
BridgeBio Pharma made up 0.11% of Candriam SCA's portfolio in Q1 2026, its #190 holding.
Candriam SCA first reported a position in BridgeBio Pharma in Q2 2021 and has held it in 15 quarters since.
Candriam SCA's BridgeBio Pharma position peaked at $27.8M in Q2 2021.
457 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q1 2026.

Based on Candriam SCA's 13F filing for Q1 2026, filed 30 Apr 2026.